Evaluation of continuous tumor-size-based end points as surrogates for overall survival in randomized clinical trials in metastatic colorectal cancer. Sci Rep. 2022;12:4206. Bayesian forecasting of tumor size metrics and overall survival. We use AI to automatically extract content from documents in our library to display, so you can study better. Support to early clinical decisions in drug development and personalised medicine with checkpoint inhibitors using dynamic biomarker-overall survival models | British Journal of Cancer. Ribba B, Holford NH, Magni P, Troconiz I, Gueorguieva I, Girard P, et al. Krishnan SM, Friberg LE.
Competing interests. Claret L, Jin JY, Ferté C, Winter H, Girish S, Stroh M, et al. A model of overall survival predicts treatment outcomes with atezolizumab versus chemotherapy in non-small cell lung cancer based on early tumor kinetics. Beumer JH, Chu E, Salamone SJ. Enhanced detection of treatment effects on metastatic colorectal cancer with volumetric CT measurements for tumor burden growth rate evaluation. A tumor growth inhibition model based on M-protein levels in subjects with relapsed/refractory multiple myeloma following single-agent carfilzomib use. Stuck on something else? Kerioui M, Desmée S, Mercier F, Lin A, Wu B, Jin JY, et al. Kerioui M, Bertrand J, Bruno R, Mercier F, Guedj J, Desmée S. Modelling the association between biomarkers and clinical outcome: An introduction to nonlinear joint models. Lin Y, Dong H, Deng W, Lin W, Li K, Xiong X, et al. Concept development for preschoolers. Measuring response in a post-RECIST world: from black and white to shades of grey.
Modeling tumor evolutionary dynamics to predict clinical outcomes for patients with metastatic colorectal cancer: a retrospective analysis. The concept of development pdf. Bratman SV, Yang SYC, Lafolla MAJ, Liu Z, Hansen AR, Bedard PL, et al. Longitudinal models of biomarkers such as tumour size dynamics capture treatment efficacy and predict treatment outcome (overall survival) of a variety of anticancer therapies, including chemotherapies, targeted therapies, immunotherapies and their combinations. This perspective paper presents recent developments and future directions to enable wider and robust use of model-based decision frameworks based on pharmacological endpoints.
Multistate pharmacometric model to define the impact of second-line immunotherapies on the survival outcome of IMpower131 study. Lone SN, Nisar S, Masoodi T, Singh M, Rizwan A, Hashem S, et al. Maitland ML, Wilkerson J, Karovic S, Zhao B, Flynn J, Zhou M, et al. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. A pan-indication machine learning (ML) model for tumor growth inhibition—overall survival (TGI-OS) prediction. Liquid biopsy: a step closer to transform diagnosis, prognosis and future of cancer treatments. Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab. Development as a concept. Rent or buy this article. Michaelis LC, Ratain MJ.
Yin A, van Hasselt JGC, Guchelaar HJ, Friberg LE, Moes DJAR. Role of Modelling and Simulation in Regulatory Decision Making in Europe. Claret L, Girard P, Hoff PM, Van Cutsem E, Zuideveld KP, Jorga K, et al. Receive 24 print issues and online access. Alternative analysis methods for time to event endpoints under nonproportional hazards: a comparative analysis. Bruno R, Mercier F, Claret L. Evaluation of tumor size response metrics to predict survival in oncology clinical trials. Cancer clinical investigators should converge with pharmacometricians. Bruno R, Marchand M, Yoshida K, Chan P, Li H, Zhu W, et al. Duda M, Chan P, Bruno R, Jin YJ, Lu J. Prices may be subject to local taxes which are calculated during checkout. All authors but JG are Roche employees and hold Roche stocks.
This is a preview of subscription content, access via your institution. Comparing circulating tumor cell counts with dynamic tumor size changes as predictor of overall survival: a quantitative modeling framework. Krishnan SM, Friberg LE, Mercier F, Zhang R, Wu B, Jin JY, et al. Received: Revised: Accepted: Published: DOI: Application of machine learning for tumor growth inhibition—overall survival modeling platform. Prediction of overall survival in patients across solid tumors following atezolizumab treatments: a tumor growth inhibition-overall survival modeling framework.
Answer & Explanation. Claret L, Girard P, O'Shaughnessy J, Hoff P, Van Cutsem E, Blum J, et al. Zou W, Yaung SJ, Fuhlbrück F, Ballinger M, Peters E, Palma JF, et al. Mezquita L, Preeshagul I, Auclin E, Saravia D, Hendriks L, Rizvi H, et al. Benzekri S, Karlsen M, El Kaoutari A, Bruno R, Neubert A, Mercier F, et al. Chatelut E, Hendrikx JJMA, Martin J, Ciccolini J, Moes DJAR. Circulating tumour cells in the -omics era: how far are we from achieving the 'singularity'? Subscribe to this journal.